Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 206

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike

Open access
Prévost, Jérémie, Gasser, Romain, Beaudoin-Bussières, Guillaume, Richard, Jonathan, Duerr, Ralf, Laumaea, Annemarie, Anand, Sai Priya, Goyette, Guillaume, Benlarbi, Mehdi, Ding, Shilei, Medjahed, Halima, Lewin, Antoine, Perreault, Josée, Tremblay, Tony, Gendron-Lepage, Gabrielle, Gauthier, Nicolas, Carrier, Marc, Marcoux, Diane, Piché, Alain, Lavoie, Myriam, Benoit, Alexandre, Loungnarath, Vilayvong, Brochu, Gino, Haddad, Elie, Stacey, Hannah D., Miller, Matthew S., Desforges, Marc, Talbot, Pierre J., Maule, Graham T. Gould, Côté, Marceline, Therrien, Christian, Serhir, Bouchra, Bazin, Renée, Roger, Michel, Finzi, Andrés·2020·Cell Reports Medicine

Published version of a preprint

Abstract

SARS-CoV-2 is responsible for the coronavirus disease 2019 (COVID-19) pandemic, infecting millions of people and causing hundreds of thousands of deaths. The Spike glycoproteins of SARS-CoV-2 mediate viral entry and are the main targets for neutralizing antibodies. Understanding the antibody response directed against SARS-CoV-2 is crucial for the development of vaccine, therapeutic, and public health interventions. Here, we perform a cross-sectional study on 106 SARS-CoV-2-infected individuals to evaluate humoral responses against SARS-CoV-2 Spike. Most infected individuals elicit anti-Spike antibodies within 2 weeks of the onset of symptoms. The levels of receptor binding domain (RBD)-specific immunoglobulin G (IgG) persist over time, and the levels of anti-RBD IgM decrease after symptom resolution. Although most individuals develop neutralizing antibodies within 2 weeks of infection, the level of neutralizing activity is significantly decreased over time. Our results highlight the importance of studying the persistence of neutralizing activity upon natural SARS-CoV-2 infection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.xcrm.2020.100126

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 25

  1. Walls, 2020, Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein, Cell, 181, 281, 10.1016/j.cell.2020.02.058 · doi:10.1016/j.cell.2020.02.058 · Paper page
  2. Yuan, 2020, A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV, Science, 368, 630, 10.1126/science.abb7269 · DOI · Paper page
  3. Shi, 2020, A human neutralizing antibody targets the receptor binding site of SARS-CoV-2, Nature, 584, 120, 10.1038/s41586-020-2381-y · DOI · Paper page
  4. Wu, 2020, A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2, Science, 368, 1274, 10.1126/science.abc2241 · DOI · Paper page
  5. Murin, 2019, Antibody responses to viral infections: a structural perspective across three different enveloped viruses, Nat. Microbiol., 4, 734, 10.1038/s41564-019-0392-y · DOI · Paper page
  6. Rouse, 2010, Immunity and immunopathology to viruses: what decides the outcome?, Nat. Rev. Immunol., 10, 514, 10.1038/nri2802 · DOI · Paper page
  7. Stadlbauer, 2020, SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup, Curr. Protoc. Microbiol., 57, e100, 10.1002/cpmc.100 · DOI · Paper page
  8. Grzelak, 2020, SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors, medRxiv
  9. Jaimes, 2020, Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop, J. Mol. Biol., 432, 3309, 10.1016/j.jmb.2020.04.009 · DOI · Paper page
  10. Zhou, 2020, A Novel Bat Coronavirus Closely Related to SARS-CoV-2 Contains Natural Insertions at the S1/S2 Cleavage Site of the Spike Protein, Curr. Biol., 30, 2196, 10.1016/j.cub.2020.05.023 · DOI · Paper page
  11. Madu, 2009, Characterization of a highly conserved domain within the severe acute respiratory syndrome coronavirus spike protein S2 domain with characteristics of a viral fusion peptide, J. Virol., 83, 7411, 10.1128/JVI.00079-09 · DOI · Paper page
  12. Sterlin, 2020, IgA dominates the early neutralizing antibody response to SARS-CoV-2, medRxiv
  13. Watanabe, 2020, Site-specific glycan analysis of the SARS-CoV-2 spike, Science, 369, 330, 10.1126/science.abb9983 · DOI · Paper page
  14. Watanabe, 2020, Vulnerabilities in coronavirus glycan shields despite extensive glycosylation, Nat. Commun., 11, 2688, 10.1038/s41467-020-16567-0 · DOI · Paper page
  15. Sok, 2018, Recent progress in broadly neutralizing antibodies to HIV, Nat. Immunol., 19, 1179, 10.1038/s41590-018-0235-7 · DOI · Paper page
  16. Yin, 2020, Longitudinal anti-SARS-CoV-2 antibody profile and neutralization activity of a COVID-19 patient, J. Infect., 81, e31, 10.1016/j.jinf.2020.06.076 · DOI
  17. Zhang, 2020, Longitudinal Change of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in Patients with Coronavirus Disease 2019, J. Infect. Dis., 222, 183, 10.1093/infdis/jiaa229 · DOI
  18. Perreault, 2020, Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within four months after symptom onset, Blood, 10.1182/blood.2020008367 · DOI
  19. Hofmann, 2005, Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry, Proc. Natl. Acad. Sci. USA, 102, 7988, 10.1073/pnas.0409465102 · DOI · Paper page
  20. Hoffmann, 2013, Differential sensitivity of bat cells to infection by enveloped RNA viruses: coronaviruses, paramyxoviruses, filoviruses, and influenza viruses, PLoS One, 8, e72942, 10.1371/journal.pone.0072942 · DOI
  21. Lodge, 1997, The membrane-proximal intracytoplasmic tyrosine residue of HIV-1 envelope glycoprotein is critical for basolateral targeting of viral budding in MDCK cells, EMBO J., 16, 695, 10.1093/emboj/16.4.695 · DOI · Paper page
  22. Liu, 2013, The interferon-inducible MxB protein inhibits HIV-1 infection, Cell Host Microbe, 14, 398, 10.1016/j.chom.2013.08.015 · DOI · Paper page
  23. ter Meulen, 2006, Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants, PLoS Med., 3, e237, 10.1371/journal.pmed.0030237 · DOI · Paper page
  24. Tian, 2020, Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody, Emerg. Microbes Infect., 9, 382, 10.1080/22221751.2020.1729069 · DOI · Paper page
  25. Desforges, 2013, The acetyl-esterase activity of the hemagglutinin-esterase protein of human coronavirus OC43 strongly enhances the production of infectious virus, J. Virol., 87, 3097, 10.1128/JVI.02699-12 · DOI

Cited by

See all 206

Metadata

Authors
Prévost, J., Gasser, R., Beaudoin-Bussières, G., Richard, J., Duerr, R., Laumaea, A., Anand, S. P., Goyette, G., Benlarbi, M., Ding, S., Medjahed, H., Lewin, A., Perreault, J., Tremblay, T., Gendron-Lepage, G., Gauthier, N., Carrier, M., Marcoux, D., Piché, A., Lavoie, M., Benoit, A., Loungnarath, V., Brochu, G., Haddad, E., Stacey, H. D., Miller, M. S., Desforges, M., Talbot, P. J., Maule, G. T. G., Côté, M., Therrien, C., Serhir, B., Bazin, R., Roger, M., & Finzi, A.
Venue
Cell Reports Medicine
Publisher
Elsevier BV
Published
2020-10
Volume
1
Issue
7
Pages
100126
ISSN
2666-3791 (ISSN-L)
OpenAlex
W3090857960
Cited by
206
References
12
FWCI
5.49
Type
journal article
Language
en
Open access
gold
Licence
Funders
  • Canadian Institutes of Health Research
  • Fondation du CHUM

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike. https://app.cochat.ai/papers/10.1016/j.xcrm.2020.100126
The paper
Prévost, J., Gasser, R., Beaudoin-Bussières, G., Richard, J., Duerr, R., Laumaea, A., Anand, S. P., Goyette, G., Benlarbi, M., Ding, S., Medjahed, H., Lewin, A., Perreault, J., Tremblay, T., Gendron-Lepage, G., Gauthier, N., Carrier, M., Marcoux, D., Piché, A., . . . Finzi, A. (2020). Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike. Cell Reports Medicine. https://doi.org/10.1016/j.xcrm.2020.100126

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.